Arcoxia COI disclosures

The FDA advisory panel committee to review Arcoxia etoricoxib from Merck (MRK) this week has been granted three conflict of interest waivers to academics with commercial ties. The panel also will include two consumer

Read the full 346 word article

How to gain access

Continue reading with a
two-week free trial.